

University of Groningen

**Response to: "Halo Score': missing large vessel giant cell arteritis- do we need a modified 'Halo Score?'" by Chattopadhyay and Ghosh**

van der Geest, Kornelis S M; Dasgupta, Bhaskar

*Published in:*  
Annals of the Rheumatic Diseases

*DOI:*  
[10.1136/annrheumdis-2020-218262](https://doi.org/10.1136/annrheumdis-2020-218262)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2022

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

van der Geest, K. S. M., & Dasgupta, B. (2022). Response to: "Halo Score': missing large vessel giant cell arteritis- do we need a modified 'Halo Score?'" by Chattopadhyay and Ghosh. *Annals of the Rheumatic Diseases*, 81, [218262]. <https://doi.org/10.1136/annrheumdis-2020-218262>

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

## Response to: "Halo Score": missing large vessel giant cell arteritis— do we need a modified 'Halo Score?' by Chattopadhyay and Ghosh

We thank Chattopadhyay and Ghosh for their interest in our paper describing a novel ultrasonographic Halo Score for giant cell arteritis (GCA).<sup>1</sup> The Halo Score quantifies the extent of inflammation in the three temporal artery segments and axillary arteries.<sup>2</sup> The total score is the sum of all halo grades, which reflect the thickness of each halo. Halo grades of the axillary arteries are multiplied by a factor of 3 in order to give equal weight to inflammation of the cranial and large systemic arteries. Chattopadhyay and Ghosh underscore the importance of ultrasonography for the diagnosis of GCA, and recognise the potential of the Halo Score for the monitoring of disease activity. The authors propose to include the subclavian artery into the Halo Score and to use it for patients with Takayasu arteritis.

Chattopadhyay and Ghosh suggest that the subclavian artery is more frequently affected by GCA than the axillary artery; and that the Halo Score could thus underestimate the extent of inflammation. The authors refer to the study by Muratore *et al*,<sup>3</sup> who used computed tomography angiography (CTA), magnetic resonance angiography (MRA) or (18F)-fluorodeoxyglucose positron-emission tomography (FDG-PET) to evaluate large vessel involvement in patients with GCA. Although this was an excellent study, it might not be suitable for comparing the involvement of subclavian and axillary arteries in GCA. The presence of an abnormal subclavian artery *per se* was the main selection criterion for patients with large vessel GCA to enter the study.<sup>3</sup> Most ultrasonography studies in GCA have actually demonstrated that arterial wall swelling more often occurs in the axillary arteries than in the subclavian arteries (table 1).<sup>4–8</sup> IWall swelling of the subclavian arteries in the absence of vasculitic changes in the axillary arteries was only seen in 2%–8% of patients with large vessel GCA.<sup>4,7</sup> It is noteworthy that the ultrasonographic assessment of the facial and occipital artery also provides limited diagnostic yield in addition to that of the temporal artery.<sup>9,10</sup> Clinical guidelines for GCA therefore recommend temporal and axillary artery ultrasonography as the first-line investigation for GCA.<sup>11,12</sup> The Halo Score correlated well with systemic inflammation (eg, C-reactive protein levels) in patients with GCA.<sup>2</sup> We believe that inclusion of the subclavian artery in the Halo Score is not essential for estimating the burden of inflammation in GCA.

Feasibility is another reason why additional arteries should not necessarily be incorporated in the Halo Score. The

investigation of more arteries will require extra time and clinical effort. Furthermore, the evaluation of particular arteries can be challenging. For instance, the subclavian artery is located deeper than the axillary artery. Lower ultrasound frequencies are therefore needed to evaluate the subclavian artery, which affects the resolution of the images. This could potentially limit the measurement of the halo thickness; especially in obese persons. The addition of more arteries to the Halo Score might affect its clinical applicability.

We agree with Chattopadhyay and Ghosh that ultrasonography is an important diagnostic modality in Takayasu arteritis. However, temporal and axillary artery involvement is not a prominent finding in Takayasu arteritis.<sup>13</sup> The Halo Score, which was developed for GCA, might not be well-suited to quantify the extent of inflammation in Takayasu arteritis. We expect that an alternative Takayasu Halo Score incorporating other large vessels could be more relevant in Takayasu arteritis.<sup>13,14</sup> This of course requires further investigation.

In conclusion, we do not believe that we need a modified Halo Score in order to estimate the burden of inflammation in patients with GCA. However, the development of a dedicated Takayasu Halo Score could be of interest.

Kornelis S M van der Geest ,<sup>1,2</sup> Bhaskar Dasgupta <sup>2</sup>

<sup>1</sup>Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

<sup>2</sup>Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, UK

**Correspondence to** Kornelis S M van der Geest, Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9712 CP Groningen, The Netherlands; k.s.m.van.der.geest@umcg.nl

**Handling editor** Josef S Smolen

**Twitter** Bhaskar Dasgupta @profbdasgupta

**Contributors** KSMG and BD wrote the manuscript, revised it critically for important intellectual content and provided final approval of the version published.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** KSMG reports grants from the Mandema Stipend and the Dutch Society for Rheumatology, and personal fees from Roche, outside the submitted work. BD reports grants and personal fees from Roche, personal fees from GSK, BMS, Sanofi and AbbVie, outside the submitted work.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** van der Geest KSM, Dasgupta B. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218262

Received 14 June 2020

Accepted 16 June 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-218224>

*Ann Rheum Dis* 2020;0:1–2. doi:10.1136/annrheumdis-2020-218262

**ORCID iDs**

Kornelis S M van der Geest <http://orcid.org/0000-0003-2798-6765>

Bhaskar Dasgupta <http://orcid.org/0000-0002-5523-6534>

**Table 1** Subclavian and axillary artery involvement in patients with large vessel GCA at diagnosis.

| Study                                | Patients with LV-GCA (n) | Patients with subclavian artery involvement (n (%)) | Patients with axillary artery involvement (n (%)) |
|--------------------------------------|--------------------------|---|---|
| Schmidt <i>et al</i> <sup>A</sup>    | 53                       | 32 (61)   | 51 (96)   |
| Ghinoi <i>et al</i> <sup>B</sup>     | 15                       | 9 (60)  | 3 (20)  |
| Czihal <i>et al</i> <sup>C</sup>     | 59                       | 36 (61)   | 53 (90)   |
| Löffler <i>et al</i> <sup>D</sup>    | 26                       | 14 (54)   | 18 (69)   |
| Aschwanden <i>et al</i> <sup>E</sup> | 42                       | 8 (19)  | 13 (31)   |

Overview of ultrasonography studies reporting a paired assessment of subclavian and axillary arteries in patients with large vessel GCA (LV-GCA) at diagnosis. No overlap in patients existed among these five studies. GCA, giant cell arteritis.

## REFERENCES

- 1 Chattopadhyay A, Ghosh A. 'Halo Score': missing large vessel giant cell arteritis - do we need a 'modified Halo Score'? *Annals of the Rheumatic Diseases* 2020. doi: 10.1136/annrheumdis-2020-218224.
- 2 van der Geest KSM, Borg F, Kayani A, *et al.* Novel ultrasonographic halo score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. *Ann Rheum Dis* 2020;79:393–9.
- 3 Muratore F, Kermani TA, Crowson CS, *et al.* Large-Vessel giant cell arteritis: a cohort study. *Rheumatology* 2015;54:463–70.
- 4 Schmidt WA, Seifert A, Gromnica-Ihle E, *et al.* Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. *Rheumatology* 2008;47:96–101.
- 5 Ghinoi A, Pipitone N, Nicolini A, *et al.* Large-Vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. *Rheumatology* 2012;51:730–4.
- 6 Czihal M, Zanker S, Rademacher A, *et al.* Sonographic and clinical pattern of extracranial and cranial giant cell arteritis. *Scand J Rheumatol* 2012;41:231–6.
- 7 Löffler C, Hoffend J, Benck U, *et al.* The value of ultrasound in diagnosing extracranial large-vessel vasculitis compared to FDG-PET/CT: a retrospective study. *Clin Rheumatol* 2017;36:2079–86.
- 8 Aschwanden M, Schegk E, Imfeld S, *et al.* Vessel wall plasticity in large vessel giant cell arteritis: an ultrasound follow-up study. *Rheumatology* 2019;58:792–7.
- 9 Ješe R, Rotar Žiga, Tomšič M, *et al.* The role of colour Doppler ultrasonography of facial and occipital arteries in patients with giant cell arteritis: a prospective study. *Eur J Radiol* 2017;95:9–12.
- 10 Pfadenhauer K, Weber H. Giant cell arteritis of the occipital arteries--a prospective color coded duplex sonography study in 78 patients. *J Neurol* 2003;250:844–9.
- 11 Dejaco C, Ramiro S, Duftner C, *et al.* EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. *Ann Rheum Dis* 2018;77:636–43.
- 12 Mackie SL, Dejaco C, Appenzeller S, *et al.* British Society for rheumatology guideline on diagnosis and treatment of giant cell arteritis. *Rheumatology* 2020;59:e1–23.
- 13 Koster MJ, Warrington KJ. Classification of large vessel vasculitis: can we separate giant cell arteritis from Takayasu arteritis? *Presse Med* 2017;46:e205–13.
- 14 Brkic A, Terslev L, Møller Döhn U, *et al.* Clinical applicability of ultrasound in systemic large vessel vasculitides. *Arthritis Rheumatol* 2019;71:1780–7.